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Polecular Mechanisms in Heart Failure
ocus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis
enise Hilfiker-Kleiner, PHD, Ulf Landmesser, MD, Helmut Drexler, MD
annover, Germany
Heart failure is a final common pathway in cardiovascular disease, as a result of sustained
pressure overload (i.e., hypertension), myocardial ischemia or infarction, volume overload
(i.e., mitral regurgitation), or inherited and acquired cardiomyopathies. Heart failure is a
major health care burden, and despite significant therapeutic advances, morbidity and
mortality in heart failure remain unacceptably high. Therefore, novel insights into patho-
physiology and molecular mechanisms of heart failure are required to develop novel
therapeutic approaches. In this review we highlight several advances in the understanding of
molecular pathways involved in cardiac hypertrophy, inflammatory signaling (i.e., tumor
necrosis factor-, interleukin-6), and oxidant stress that may play a key role in altering
transcriptional regulatory networks regulating adaptation or maladaptation, and consequently,
the transition to overt heart failure. In this respect we focus on paracrine mechanisms
(vascular endothelial growth factor, CCN1) and intracellular signaling (interleukin-6–
glycoprotein 130–signal transducer and activator of transcription-3). In addition, we
highlight the impact of current treatment options on these molecular pathways and their
potential impact on progression of heart failure. (J Am Coll Cardiol 2006;48:A56–66)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.007© 2006 by the American College of Cardiology Foundation
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neart failure is a leading cause of hospitalization and
ortality worldwide. Despite significant therapeutic ad-
ances, the morbidity and mortality of heart failure remain
nacceptably high. Heart failure is a final common pathway
f various cardiovascular diseases, including sustained pres-
ure overload (i.e., hypertension), myocardial ischemia or
nfarction, volume overload (i.e., valvular heart disease), and
nherited or acquired cardiomyopathies.
Myocardial hypertrophy is a major predictor of progressive
eart disease and an adverse prognosis. Myocardial hypertro-
hy is a response of cardiac muscle to altered conditions caused
y a large number of physiological and pathological stimuli.
Physiological cardiac hypertrophy” occurs in response to
rowth, exercise, or pregnancy, in which cardiomyocyte hyper-
rophy is paralleled by a proportional growth of the vasculature
nd the capillary network and is usually not accompanied by
ardiac fibrosis (1). At the molecular levels, physiological
ypertrophy seems to be characterized by increased expression
f adult isoforms of sarcomeric genes (i.e., -myocin heavy
hain [MHC], cardiac -actin) (1,2). Pathological hypertro-
hy in response to pathophysiological stress signals (e.g.,
eurohormonal activation, aortic stenosis, inflammation or
ardiac injury) may be initially adaptive in terms of muscular
conomy, normalizing wall stress, and preserving contractile
erformance, but can proceed to decompensation and heart
ailure. Notably, at the molecular level pathological hypertro-
hy is characterized by the activation of gene expression
atterns of the fetal stage, which includes an up-
egulation of fetal isoforms of genes whose products
From the Departments of Cardiology and Angiology, Hannover Medical School,
annover, Germany. Supported by the Deutsche Forschungsgemeinschaft and the
ean Leducq Foundation.p
Manuscript received December 8, 2005; revised manuscript received May 25, 2006,
ccepted June 6, 2006.egulate cardiac contractility and calcium handling,
hich is often paralleled by a down-regulation of their
dult isoforms (i.e., up-regulation of -MHC vs. down-
egulation of -MHC) (1,2). Pathological hypertrophy is
ften associated with impaired myocardial vascularization,
nfavorable changes in the extracellular matrix composition,
nd fibrosis (3,4). More recently, evidence has been presented
howing that pathophysiological stresses also interfere with the
ormal cell turnover in the heart, leading to an unfavorable
atio of cardiac apoptosis and regeneration from circulating and
ardiac progenitor cells (5).
The last decade has seen a major advance in the under-
tanding of molecular mechanisms of adaptive and mal-
daptive hypertrophy and heart failure in response to stress
ignals and has shown that a multitude of extracellular
actors and signaling pathways are involved. In this regard,
daptive myocardial hypertrophy has been associated with
rowth hormone/insulin-like growth factor-1, interleukin-6
IL-6) cytokines/glycoprotein 130 (gp130) and biomechani-
al stretch signaling and seems to involve the activation of
he phosphatidylinositol 3-kinase (PI3-K)/protein kinase B
Akt)/glycogen synthase kinase 3 cascade, the signal trans-
ucer and activator of transcription 3 (STAT3), and/or
ctivation of extracellular signal-regulated kinases (ERK)
6–9). These signaling pathways have been implicated in
daptive hypertrophy because their overexpression or con-
titutive activation leads to increased cardiomyocyte size and
oncentric hypertrophy in the absence of fibrosis, with
reserved systolic function (6,8,9). In contrast, maladaptive
yocardial hypertrophy has been associated with angioten-
in II, tumor necrosis factor- (TNF-), and cat-
cholamines (7,10) and seems to involve downstream sig-
aling pathways, c-Jun N-terminal kinase and p38, which
romote cardiac fibrosis and apoptosis (11).
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November 7, 2006:A56–66 Molecular Mechanisms in Heart FailureConceivably, sustained pathophysiological stress may
romote the transition of initially adaptive hypertrophy and
emodeling into a decompensated stage with cardiac con-
ractile dysfunction, clinical signs of heart failure, and
remature death. This process, termed maladaptive remod-
ling, has been linked to biological processes provided by
ctivated stress pathways.
At the Symposium on Cardiovascular Disease held by the
ondation Leducq in Paris, France, October 2005, we high-
ighted recent mechanistic findings in some molecular path-
ays related to heart failure such as cardiac hypertrophy,
nflammation, angiogenesis, and apoptosis. Because of limits in
pace, other important aspects, such as excitation-contraction
oupling, calcium signaling, and the beta-adrenergic receptor
athway are not discussed and the reader is referred to excellent
eviews on these topics (12–14).
EUROHORMONAL STIMULATION OF
ARDIAC HYPERTROPHY AND DYSFUNCTION
he understanding of the important role of neurohormonal
ctivation in the pathophysiology of heart failure has paved
he way for the current medical treatment to improve
orbidity and mortality in patients with heart failure (15).
esides angiotensin II–induced signaling mediated by the
T-1 receptor and sympathetic activation, increased aldo-
terone production, at least in part angiotensin II indepen-
ent, has been suggested to play a major role in left
entricular (LV) remodeling and LV dysfunction. Accord-
ngly, recent experimental data support the concept that
ldosterone blockade exerts beneficial effects in addition to
ffective renin-angiotensin system blockade. In AT-1A-
eceptor-deficient mice, cardiac gene expression levels of
ldosterone synthase were elevated after myocardial infarc-
ion and LV remodeling and dysfunction were attenuated by
pironolactone in these mice (16). Furthermore, Fiebeler
Abbreviations and Acronyms
Akt  protein kinase B
ERK  extracellular signal-regulated kinases
gp130  glycoprotein 130
GSK  glycogen synthase kinase
IL-6  interleukin-6
JAK  Janus kinase
LIF  leukemia inhibitory factor
LV  left ventricle/ventricular
MHC  myosin heavy chain
MLP  muscle limb protein
NF-kappaB  nuclear factor kappaB
NO  nitric oxide
PI3-K  phosphatidylinositol 3-kinase
ROS  reactive oxygen species
STAT3  signal transducer and activator of
transcription
TNF-  tumor necrosis factor-
VEGF  vascular endothelial growth factort al. (17) have recently provided experimental evidence chowing that increased cardiac damage caused by aldo-
terone may be secondary to increased adrenal aldoste-
one production, because both adrenalectomy and aldoste-
one synthase (CYP11B2) inhibition reduced cardiac
ldosterone levels and prevented cardiac hypertrophy and
eath in renin-angiotensin transgenic rats. Aldosterone is
ne of the stimulators of cardiomyocyte reactive oxygen
pecies (ROS) production (18) that has been implicated in
he development of cardiac hypertrophy and dysfunction in
esponse to both biomechanical and neurohormonal stimuli.
NCREASED OXIDANT SIGNALING IN HEART FAILURE
umerous studies have reported increased myocardial produc-
ion of ROS (superoxide, hydrogen peroxide, hydroxyl radical)
n experimental and clinical heart failure (19–21). Recent work
as characterized potential sources of increased ROS produc-
ion in failing myocardium, including NAD(P)H and xanthine
xidase, dysfunctional nitric oxide synthase, and the mitochon-
rial electron transport chain (22–24). Two recent studies have
eported increased NAD(P)H oxidase activity in human failing
ompared with nonfailing left ventricles (22,25). Maack et al.
22) have further provided evidence for an increased expres-
ion of the NAD(P)H oxidase subunit p47phox and in-
reased activity of the small G protein rac-1, thought to be
mportant for activation of the NAD(P)H oxidase enzyme
omplex, in patients with heart failure. Bendall et al. (26)
ave shown that angiotensin II–induced cardiac hypertro-
hy after 2-week treatment was dependent on NAD(P)H
xidase activation. Interestingly, increased NAD(P)H oxi-
ase activation may therefore represent a potential treat-
ent target for preventing cardiomyocyte hypertrophy in
eart failure. Of note, statins prevent membrane transloca-
ion of the small G protein Rac-1 (because of inhibited
soprenylation) and are thought to thereby inhibit
AD(P)H oxidase. This may contribute to the prevention
f cardiac hypertrophy and dysfunction after statin treat-
ent that has been observed in numerous experimental
tudies (27–30). Recent in vitro and in vivo studies have
rovided evidence for an important role of antioxidant
ffects of statins for their effect on cardiac hypertrophy (27)
nd vascular dysfunction in patients with heart failure (Fig.
) (29).
Increased myocardial and vascular xanthine oxidase activ-
ty has been observed in human heart failure (31,32).
xperimental studies have suggested beneficial effects of
igh-dose treatment with allopurinol, a xanthine oxidase
nhibitor, on LV dysfunction and remodeling (33) and
otentially increased survival in mice after myocardial in-
arction (34). In patients with chronic heart failure, in-
reased serum levels of uric acid, the product of xanthine
xidase, have been associated with an adverse prognosis
35). In a small clinical study, acute xanthine oxidase inhibition
ith intracoronary allopurinol improved LV efficiency in pa-
ients with idiopathic dilated cardiomyopathy (31). A larger
linical study has been performed in 405 patients with class III
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Molecular Mechanisms in Heart Failure November 7, 2006:A56–66o IV heart failure over 24 weeks (OPT-CHF [Controlled
fficacy and Safety Study of Oxypurinal Added to Standard
herapy in Patients with NewYorkHeart Association class III
o IV Congestive Heart Failure] trial) using oral xanthine
xidase inhibition by oxypurinol; however, the results of this
tudy have not been published.
A detailed understanding of the pathophysiologically
elevant sources of ROSs and their role in heart failure will
e necessary to possibly limit cardiac hypertrophy and
ysfunction. Another major consequence of increased ROS
roduction in heart failure is a loss of endothelial nitric
xide synthase (NOS)-derived nitric oxide (NO), which reacts
ery rapidly with superoxide, leading to formation of the toxic
eroxynitrite, and may contribute to impaired peripheral vas-
ular function and coronary perfusion (36,37). In this respect
e and others have observed an improved endothelium-
ependent, NO-mediated vasodilation after administration
f a high dose of the antioxidant vitamin C in patients with
eart failure (37) or after treatment with the superoxide
cavenger superoxide dismutase in experimental heart failure
36). In addition, accumulating experimental data suggest
n important role of reduced endothelial nitric oxide
ynthase-dependent NO availability in heart failure that
ay augment LV remodeling and dysfunction (30,38–40).
n addition, several recent clinical studies have closely linked
he degree of endothelial dysfunction, thought to indicate a
educed endothelial NO availability, with an adverse clinical
utcome in patients with heart failure (41–43). Notably, recent
ata have implicated a protective role of the neuronal NO
ynthase, because neural NOS-deficient mice had an aug-
ented LV remodeling in experimental heart failure (40,44).
In summary, increased ROS production is likely involved
n key aspects relevant to the development and the progres-
ion of heart failure, such as cardiomyocyte hypertrophy,
igure 1. Statin therapy may represent a potentially novel treatment
ascularization. Statins may exert beneficial effects in heart failure independ
uch as Rac-1 or Rho-A, which have been shown to be critically involved
f endothelial nitric oxide (NO) synthase expression. Prevention of NAD(P
vailability may reduce cardiomyocyte hypertrophy and improve vascular (entricular dysfunction, and endothelial dysfunction. A fherapy that may exert beneficial effects in heart failure by
educing oxidant stress and increasing endothelial NO
vailability is statin treatment. Statins have been shown to
nhibit NADPH oxidase activation in the cardiomyocyte
45) and at the same time to increase endothelial cell NO
roduction (46). The proposed mechanisms by which st-
tins may exert beneficial effects in heart failure independent
f cholesterol lowering are shown in Figure 1.
NFLAMMATORY SIGNALING IN HEART
AILURE: WHAT IS DOWNSTREAM OF TNF-?
t is well established that increased levels of TNF- appear
n the circulation of patients with heart failure, and together
ith the soluble TNF- receptors 1 and 2 serve as prog-
ostic markers in these patients (47,48). The observation
hat mice harboring a transgene that selectively overex-
resses TNF- in the heart developed cardiac hypertrophy
nd dilated cardiomyopathy implicated a detrimental role of
his cytokine in the heart (49). In addition, TNF- exerts
trong direct effects on cardiomyocytes, as it induces apo-
tosis, depression of contractility, and down-regulation of
arcomeric proteins in cardiomyocytes in vitro (50–52).
herefore, a causal role of TNF- in heart failure seemed to
e obvious and clearance of TNF- as a novel therapeutic
trategy was hoped to improve heart failure. Clinical pilot
rials in small patient collectives showed that clearance of
NF- improved cardiac performance in heart failure
reviewed by Torre-Amione [48]). However, the outcomes
f 2 large-scale clinical trials (with etanercept and inflix-
mab) that directly antagonized TNF- have been rather
isappointing and suggested that counterbalancing this
ytokine alone may not be sufficient (53).
More recently, novel promising strategies have emerged
gy for preventing cardiac hypertrophy and for improving myocardial
f cholesterol lowering by prevention of isoprenylation of small g proteins,
e activation of the oxidant enzyme NAD(P)H oxidase and the regulation
idase activation and an increased endothelial NO synthase-dependent NO
ndothelial) function.strate
ent o
in throm experimental work targeting specifically downstream
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November 7, 2006:A56–66 Molecular Mechanisms in Heart Failureignaling pathways of TNF-. In this regard, the nuclear
actor kappaB (NF-kappaB) was robustly activated in mice
ith cardiac-specific activation of TNF-, and this activa-
ion was mediated via the TNF- receptor 1 (54). In mice
ouble mutant for the TNF- transgene and a knockout of
he p50 subunit of NF-kappaB, cardiac function and sur-
ival was significantly improved compared with mice har-
oring the TNF- transgene alone (55). Thus, NF-kappaB
eems to be an important mediator of the detrimental effects
f TNF- signaling in the heart. Further evidence for a
egative role of activated NF-kappaB in the stressed heart
as obtained from experiments using NF-kappaB inhibit-
ng decoy oligonucleotides, which significantly reduced the
nfarct size after experimental myocardial infarction (56).
F-kappaB is also activated in failing human hearts of
arious etiologies, implicating a role of this transcription
actor in the pathophysiology of human heart failure
57,58). However, care must be taken because NF-kappaB
ctivation seems not always detrimental for the heart. In this
egard, pharmacologic inhibition of NF-kappaB abolished
he protective effect of ischemic preconditioning (short
eriods of ischemia and reperfusion) on reduction of the
nfarct size during reperfusion (59).
The role of TNF- signaling in the heart is complex and
eems to depend on the nature of stress and the interplay of
ownstream inflammatory mediators. Therefore, detailed
nalysis and understanding of the signaling networks un-
erlying TNF-– mediated inflammatory processes in car-
iomyopathies of different etiologies is essential for devel-
ping novel therapies targeting specifically the detrimental
iological effects of TNF-.
HE MANY FACETS OF
ARDIOPROTECTION BY
L-6–gp130–STAT3 SIGNALING
ome years ago it was reported that IL-6 cytokine levels are
levated in patients with heart failure and that IL-6 is a
trong prognostic marker for the morbidity and mortality in
atients with heart failure or after myocardial infarction
60,61). More recently, our laboratory has explored the
L-6–gp130–Janus kinase (JAK)–STAT signaling cascade
n patients with end-stage heart failure and showed that this
ignaling cascade is altered at each level in failing human
earts (62) (Fig. 2). For example, the cardiac expression of
L-6 (Fig. 2) is reduced, whereas the expression of IL-6
amily member leukemia inhibitory factor (LIF) is elevated.
he expression of cardiotrophin-1, another member of the
L-6 cytokine family, is not altered (62). At the receptor
evel we observed that gp130 expression is not different, but
ailing hearts show enhanced gp130 activation (tyrosine
hosphorylation) (Fig. 2). The expression of JAK2, the next
ownstream signaling molecule of the gp130 receptor, is
lso not altered, but surprisingly its activation state (tyrosine
hosphorylation) is diminished in failing hearts (Fig. 2).
ost strikingly, the effector signaling molecule of the iL-6–gp130 cascade, STAT3, is severely reduced in failing
earts (Fig. 2) (62). Although these observations do not
dentify the exact role of individual factors within the
L-6–gp130–JAK–STAT signaling system, a growing
ody of experimental work indicates that IL-6–related
ytokine signaling contributes to compensatory hypertro-
hy, provides cardioprotection, and promotes neovascular-
zation in the stressed heart (63–68). In particular, the
nalysis of transgenic mice harboring knockouts for specific
omponents of the IL-6–gp130–JAK–STAT cascade
heds light on the role of this signaling pathway in the
athophysiology of the heart. For example, mice with a
ystemic deficiency of IL-6 were not different from wild
ypes regarding their basal cardiac phenotype, respectively
oncerning infarct size, cardiac function, and survival after
yocardial infarction (Fig. 2), most likely because IL-6
ytokines are redundant, and other proinflammatory cyto-
ines such as LIF can compensate for the lack of IL-6 (69).
owever, infusion of an IL-6/soluble IL-6 receptor com-
lex inhibited cardiomyocyte apoptosis and limited infarct
ize after ischemia/reperfusion (70), suggesting a rather
rotective role of IL-6. LIF induces hypertrophy and
romotes survival of cardiomyocytes in vitro and in vivo
71,72). Furthermore, injection of LIF promoted healing
fter myocardial infarction (73). Cardiotrophin-1 also stim-
lates cardiomyocyte hypertrophy and seems to be involved
n wound healing after myocardial infarction (74,75). Im-
ortantly, IL-6 cytokine signaling via gp130 involves acti-
ation of 3 major pathways: MEK/ERK; JAK/STAT, and
I3-K/Akt, and each of these pathways seems to be
nvolved in hypertrophic and protective signaling in the
eart in vivo and in vitro (63,76). Although IL-6 cytokines
ight be redundant in exerting cardioprotective effects,
pparently they differ in the induction of the activation
attern of the gp130 downstream signaling. For example,
p130-mediated activation of the mitogen-activated protein
inase (MEK)/ERK signaling pathway by cardiotrophin-1
nduces hypertrophy (75), whereas LIF promotes cardiac
ypertrophy and protection via gp130-mediated activation
f the JAK2/STAT3 pathway (77).
Notably, activation of STAT3, via the gp130 receptor
ystem is essential for cardiomyocyte hypertrophy and cytopro-
ection in cardiomyocytes subjected to ischemia or toxic stress
76–78). Moreover, STAT3 is necessary for the cardioprotec-
ive effects induced by ischemic preconditioning and various
harmacologic preconditioning programs (79), and STAT3 is
lso required to protect the heart from ischemia/reperfusion
njury and myocardial infarction (Fig. 2) (67). Recent data
rom our laboratory and others provide evidence that
TAT3 plays a crucial role in the protection of the heart
uring aging (67,68) (Fig. 2). One reason why STAT3
ould provide protection in response to such a wide array
f physiological and pathophysiological stresses may
esult from its ability as a transcription factor to directly
nduce the expression of antiapoptotic and cytoprotective
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Molecular Mechanisms in Heart Failure November 7, 2006:A56–66roteins, such as Bcl-xL, heat shock protein 70, and manga-
ese superoxide dismutase, in cardiomyocytes (66,67,77).
Taken together, the IL-6–gp130–STAT3 signaling cas-
ade in human failing hearts is deregulated at all levels.
nalysis in various knockout mouse models showed that the
p130 receptor system and specifically its downstream media-
or STAT3 plays a key functional role for cardioprotection
gainst physiological and pathophysiological stress by promot-
ng cardiomyocyte survival, inducing compensatory hypertro-
hy and preserving cardiac function (Fig. 2). Thus, in the light
f these experimental data sets, elevated IL-6 serum levels in
atients with heart failure seem to be protective rather than
etrimental with respect to gp130 signaling.
OVEL INSIGHTS INTO
IOMECHANICAL SIGNALING IN HEART FAILURE
echanical stress is considered a major trigger of cardio-
yocyte growth in response to pressure overload. The
ransduction of mechanical stress into biomechanical signals
s thought to be largely mediated by a group of surface
igure 2. Comparison of the interleukin (IL)-6–glycoprotein 130 (gp130)
ignal cascade in end-stage failing human hearts with the cardiac phenotype
eft side indicates the alterations in the IL-6–gp130–JAK–STAT3 casc
yocardium: Serum levels of IL-6 are upregulated and myocardial IL-6 pr
tage (tyrosine phosphorylation) is enhanced; JAK2 activation (tyrosine ph
s reduced at both the protein level and the activation stage (tyrosine phosp
ith mutations in the IL-6–gp130–JAK–STAT3 signaling cascade. Mice
t baseline or after myocardial infarction (69); mice with cardiac-restricted
ormal at baseline but show early cardiac failure and enhanced mortality a
ith cardiac-restricted deletion of STAT3 (-MHC-Cretg/; STAT3fl
usceptible to ischemic injury (67). In summary, the gp130–STAT3 casc
tressed heart (4,63–66,68).eceptors called integrins (Fig. 3) that link the extracellular matrix to the cellular cytoskeleton, thus providing physical
ntegration between the outside and inside of the cell. The
-disc, a multiprotein complex located at the interface of
he cytoskeleton, the contractile apparatus, and the sarco-
emma in cardiomyocytes are thought to be essential for
iomechanical stress signaling in the heart (80,81).
Activation of integrins by different ligands in the extra-
ellular matrix (e.g., collagen, fibronectin laminin) initiates
ignaling in multiple intracellular pathways through
ntegrin-bound proteins (Fig. 3). One of the biomechanical
ensors in this pathway is melusin (Fig. 3), a muscle-specific
rotein that interacts with the integrin 1 cytoplasmic
omponent. Brancaccio et al. (80) have shown that melusin
s required to promote adaptive hypertrophy in response to
echanical but not to hormonal stress. Furthermore, it has
een shown that the intracellular signaling pathways regu-
ated by melusin involve ERK1/2, PI3-K/Akt and glycogen
ynthase kinase 3-beta (GSK-3) (Fig. 3) (80). A deficiency
f melusin has resulted in an early onset of cardiac dilation
nd dysfunction after pressure overload, suggesting that
s kinase (JAK)–signal transducer and activator of transcription 3 (STAT3)
ice harboring systemic or cardiac-restricted knockouts in this cascade. The
n end-stage human dilated cardiomyopathy in comparison with normal
levels are reduced; gp130 protein levels are not altered, but their activation
orylation) is diminished with no alteration in protein expression; STAT3
tion) (60–62). The right side summarizes the cardiac phenotypes of mice
systemic deletion of IL-6 (IL-6/) have no apparent cardiac phenotype
n of gp130 (-myosin heavy chain [MHC]-Cretg/; gp130flox/flox) appear
essure overload induced by thoracic aortic constriction (TAC) (63). Mice
develop an age-related dilated cardiomyopathy (67,68) and are more
eems to promote hypertrophy, cardioprotection, and angiogenesis in the–Janu
of m
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with
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fter pr
ox/flox)elusin is required for the compensatory cardiac hypertro-
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November 7, 2006:A56–66 Molecular Mechanisms in Heart Failurehy initially preventing ventricular dilation. Vice versa,
ardiac overexpression of melusin reduced ventricular dila-
ion in response to pressure overload and resulted in a
rolonged compensatory hypertrophy (82). A potential
eneficial role of downstream Akt signaling in terms of
daptive hypertrophy is supported by transgenic mice with a
oderate cardiac specific overexpression of Akt, which
evelop a concentric myocardial hypertrophy in the absence
f fibrosis with preserved systolic function (83). In turn, the
mportance of down-regulating GSK-3 for adaptive hy-
ertrophy is manifested by the observation that cardiac
ypertrophy is inhibited in mice with a cardiomyocyte-
pecific overexpression of a constitutively active form of
SK-3 in response to pressure overload (84). Similarly, a
ack of Fas receptor-induced inhibition of GSK-3 by
ressure overload coincided with a rapid onset of left
entricular dilatation and heart failure caused by the absence
f compensatory hypertrophy (85). One mechanism by
hich GSK-3 attenuates cardiac hypertrophy lies in its
bility to phosphorylate the hypertrophy-associated tran-
cription factors nuclear factor of activated T-cells (NF-AT)
nd GATA4, thereby causing their nuclear exit with the
igure 3. Sensing and transmission of stress signaling in cardiomyocyte exp
,) by different ligands in the extracellular matrix (e.g., collagen, fibron
Mel), an integrin-bound protein, transduces the stress signal from the cell m
inase (GSK)-3, thereby promoting the dephosphorylation (activation an
ctivated T-cells (NF-AT3). NF-AT3 then contributes to the induction o
80,87,93). A second stress-sensing pathway involves muscle LIM protein (
T-cap), vinculin (Vin), and talin (Tal), is anchored to integrins (,) at th
ontractile machinery to the extracellular matrix proteins laminin and colla
-cap, and seems to be necessary to keep these proteins in place during cont
t the Z-disc, where it brings calcineurin in close approximation with T-tu
a2/calmodulin after Ca2 influx. Activation of calcineurin then promoteonsequence that hypertrophic gene expression in response vo hypertrophic stimuli is lowered (86). Therefore, it has
een proposed that melusin via activating Akt signaling and
ubsequent silencing of GSK-3 activates a prohypertrophic
ene program required for compensatory hypertrophy in the
eart exposed to increased biomechanical stress (Fig. 3).
hus, selective activation of melusin may protect the chron-
cally pressure-overloaded heart from the transition toward
ilation and failure and should be explored therapeutically.
The contractile machinery of the cardiomyocyte, the sarco-
ere, is anchored to integrins at the plasma membrane via a
umber of Z-disc proteins, including, among others,
-actinin, vinculin, and talin (87). The Z-disc functions as a
hysical anchor for myofilament and cytoskeletal proteins and
s a coordination center for the reception and transduction of
echanical and biochemical stress signals. It has been shown
hat mutations in Z-disc proteins, which affect both the
tructural integrity of the Z-disc and/or the transmission of
ntracellular signals, promote dilated cardiomyopathy in mice
81,88,89). For example, muscle LIM protein (MLP), which is
ethered to the Z-disc via its interacting partners -actinin and
elethonin, has been identified as an essential part of the
echanical stretch sensor machinery and is likely to be in-
to biomechanical stretch. Mechanical strain induces activation of integrins
laminin), initiating signaling of multiple intracellular pathways. Melusin
rane to the nucleus by activating protein kinase B (Akt)-glycogen synthase
lear location) of the prohypertrophic transcription factor nuclear factor of
rohypertrophic gene program and subsequent cardiomyocyte hypertrophy
), a Z-disc protein, which with others, such as -actinin (-act), telethonin
ma membrane and to the sarcomere. This molecule complex connects the
87). MLP acts as an anchoring protein for other Z-disc proteins, e.g., for
n (81). In addition, MLP functions as an anchoring protein for calcineurin
L-type Ca2-channels, which are implicated in calcineurin activation by
activation of NF-AT3, resulting in hypertrophic gene expression (91,115).osed
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Molecular Mechanisms in Heart Failure November 7, 2006:A56–66ardiomyocytes (81,90). Knoll et al. (81) have shown that
LP knockout mice spontaneously develop dilated cardiomy-
pathy within a few weeks after birth. Moreover, MLP-
eficient cardiomyocytes display severe defects of tension
evelopment in response to mechanical stretch (81). Our group
91) has recently shown thatMLP acts as an anchoring protein
or calcineurin at the Z-disc (92) (Fig. 3) and that MLP is
equired for calcineurin activation after myocardial infarction.
-disc anchorage brings calcineurin in close proximity with
-tubular L-type Ca2-channels, which have previously been
mplicated in calcineurin activation in cardiomyocytes (93).
otably, it has been shown that calcineurin via dephosphory-
ation of NF-AT3 induces cardiomyocyte hypertrophy (94),
uggesting that MLP via calcineurin and NF-AT may provide
n additional pathway for adaptive hypertrophy in response to
echanical stress (Fig. 3).
MLP plays an important role in the human heart because
oss of function mutations in MLP have been linked to rare,
ereditary forms of dilated and hypertrophic cardiomyopa-
hy in humans (81). Interestingly, myocardial MLP expres-
ion levels are reduced by about 50% in patients with heart
ailure after myocardial infarction, suggesting that reduced
LP expression may also play a role in more common,
cquired forms of heart failure (95).
Thus, mechano-transduction signaling in cardiomyocytes
s likely to operate via the melusin–PI3-K/Akt and the
LP–calcineurin signaling pathways and promotes hyper-
rophy via activation of NF-AT3 (81,87,91,94) (Fig. 3).
ene mutations aborting one of these pathways result in an
nadequate hypertrophic response and early cardiac failure in
esponse to mechanical stress (81,87,91), implying that the
ctivation of these 2 signaling pathways is important for
romoting adaptive hypertrophy and for preventing early
ilation and failure during hemodynamic overload.
ASCULARIZATION IN THE STRESSED HEART
yocardial perfusion is a key requisite for myocardial
omeostasis. Pathophysiological stresses such as myocardial
nfarction or pressure overload enhance oxygen demand (3).
herefore, failure to induce sufficient neovascularization
esults in deficient oxygen supply and subsequently in loss
nd degeneration of cardiomyocytes, atrophy, and intersti-
ial fibrosis, and may represent a major cause of myocardial
ysfunction and heart failure (3,4,96,97). In line with this
ypothesis, fewer capillaries have been observed in many forms
f human adaptive cardiomyopathies, including end-stage
ilated cardiomyopathy (3,4,98,99). Thus, impaired capillary
rowth and the resultant metabolic imbalance may be an
mportant contributor to the transition to heart failure (3,99).
Among the signaling molecules involved in the expres-
ion of proangiogenic factors in cardiomyocytes, STAT3
eems to play a crucial role. Mice with cardiomyocyte-
pecific overexpression of STAT3 present increased capil-
ary density accompanied by enhanced expression of the
roangiogenic factors vascular endothelial growth factor mVEGF) and VE-cadherin (100). In contrast, mice with a
ardiomyocyte-specific deletion of STAT3 show a subse-
uent reduction in myocardial capillary density and cardiac
ailure (67) (Fig. 4). In the absence of STAT3, an antian-
iogenic gene program emerges that involves the up-
egulation of multiple antiangiogenic factors (67), implicat-
ng a key functional role of STAT3 in the regulation of
ngiogenic circuits in the mature heart (4).
Mice lacking JunD, a transcription factor activator
rotein-1 transcription factor, show a high rate of mortality
n response to severe pressure overload, associated with an
ncrease in cardiac apoptosis (101), most likely as a conse-
uence of enhanced oxidative stress (101). Remarkably,
hronic moderate pressure overload in JunD knockout mice
voked a more pronounced hypertrophy and strongly pro-
oted expression of VEGF and myocardial vascularization
Fig. 4B) without adverse effects on survival and cardiac
unction. Thus, JunD exerts protection in the acutely
ressure overloaded heart, but it attenuates neovasculariza-
ion in the chronic stage of pressure overload and may
hereby cause hypoxia and promote the transition into the
ecompensated stage (101).
Both STAT3 and JunD regulate the expression of the
roangiogenic secreted factor VEGF, pointing to a key role
f this protein for postnatal myocardial angiogenesis, in
hich cardiomyocytes themselves play an important role as
source for VEGF. In fact, mice with a cardiomyocyte-
pecific deletion of VEGF show less coronary microvascu-
arization and display an induction of hypoxia-responsive
enes (102). In line with these findings, application of
EGF has been shown to induce angiogenesis in many
nimal models (reviewed by Isner and Losordo [103]).
owever, transgenic mice with an inducible VEGF trans-
ene showed abnormal vascular trees, chaotic connections
ith the existing network, and formation of irregularly
haped sac-like vessels. The VEGF also caused a massive
nd highly disruptive edema in transgenic mice (104). Thus,
he therapeutic potential of VEGF to induce sustained
ardiac neovascularization is limited, and its application in
umans has yielded equivocal long-term results (105).
We have recently shown that a second proangiogenic
actor, CCN1, is induced in the heart in vivo and in
ardiomyocytes in vitro by various extracellular stress-related
timuli such as neurohumoral activation, cytokines, me-
hanical stress, and ischemia (106). CCN1 is also highly
xpressed in cardiomyocytes and vascular cells of human
ailing hearts with ischemic cardiomyopathy (106) (Fig. 4C)
nd acts as a proangiogenic factor by promoting integrin-
ediated migration and adhesion as well as survival of
ndothelial cells, vascular smooth muscle cells, fibroblasts,
nd monocytes (107). We have shown that cardiomyocytes
ecrete CCN1 and that this secreted protein is able to
nduce migration of smooth muscle cells in vitro (106).
hus, CCN1 could induce a more complete set of angio-
enic stimuli than VEGF and may therefore lead to a more
ature vessel type. The potential therapeutic effects of
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xplored in our laboratory.
In summary, cardiac neovascularization is not depen-
ent on one single gene or factor, but relies on the
egulation of multiple factors by various signaling path-
ays. Moreover, the cardiomyocyte seems to be an
mportant source for proangiogenic factors. Novel ther-
peutic strategies applying directly proangiogenic factors
r promoting the endogenous secretion of angiogenic
actors to enhance neovascularization in injured, over-
oaded, and failing hearts are warranted.
POPTOSIS AND HEART FAILURE
poptosis is involved in cell loss of cardiomyocytes during
volving heart failure. Apoptotic pathways are widely in-
uced in cardiomyocytes in the context of ischemia/
eperfusion injury over a limited time frame (108,109). In
ontrast to high rates of apoptosis in acute ischemia-
eperfusion, heart failure is characterized by very low—but
bnormal—levels of cardiomyocyte apoptosis that persist for
onths to years. In this regard, apoptosis rates of 0.08% to
.25% in patients with end-stage dilated cardiomyopathy
ave been described, compared with 0.001% to 0.002% in
onfailing control hearts (110). Although apoptosis rates in
ailing hearts are significantly increased, their principal
unctional role for the development of heart failure has
emained elusive. However, there is now evidence showing
hat apoptosis may contribute to the development of heart
ailure. In this respect, Wenker et al. (111) have addressed
igure 4. Angiogenic circuits in the heart. (A) Immunohistochemical stainin
ensity in 4-month-old -MHC-Cretg/; STAT3flox/flox male mice compa
verload augments capillary density in JunD knockout male mice (JunD/)
solectin B4 (yellow), cell membrane marker wheat germ agglutinin (red), and
xpression of CCN1 protein in cardiomyocytes and blood vessels of a left vent
ardiomyopathy (ICM) compared with low CCN1 staining in a LV section fr
ntibody-detecting sarcomeric myosin heavy chain identifies cardiomyocytes ahis issue in transgenic mice with a heart-restricted expres- mion of a procaspase-8 fusion protein, whose dimerization
nd activation could be pharmacologically induced. The
ctivation of caspase-8 is a central step in apoptosis initiated
y the activation of cell surface death receptors (e.g.,
as/FasL) (110). On activation, caspase-8 subsequently
leaves and activates among others procaspases-3, which in
urn activates downstream proapoptotic effector proteins such
s Bax and Bad and subsequently the release of cytochrome c
cyt c) and other apoptogens from mitochondria (reviewed
y Foo et al. [110]). Not surprisingly, therefore, activation
f the procaspase-8 transgene in mice has led to high
ortality within a few hours after pharmacologic stimula-
ion. Surprisingly, however, even without the activating
rug procaspase-8, transgenic mice showed a slightly in-
reased ongoing rate of apoptosis (about 10-fold higher
han in wild-type siblings), which was associated with a
rofound dilated cardiomyopathy and a high long-term
ortality rate (111). Notably, treatment with a broad-
pectrum caspase inhibitor, starting before cardiac decom-
ensation, prevented dilation and attenuated cardiac dys-
unction in procaspase-8 transgenic mice (111). The broad-
pectrum caspase inhibitor also attenuated heart failure in a
econd transgenic mouse model with peripartum cardiomy-
pathy due to overexpressing of a subunit of the heterotri-
eric guanine nucleotide-binding (G) proteins (112).
oreover, caspase inhibitors reduced infarct size after
yocardial infarction (113). Notably, these effects of caspase
nhibition always correlated with inhibition of cardiomyo-
yte death, suggesting that the major benefit of this treat-
isolectin B4 in in-situ fixed myocardial cross-section shows reduced capillary
ith age-matched wild-type (WT) sibling males (67). (B) Chronic pressure
igher degree than in WT sibling male mice, as shown by triple staining for
ar stain Hoechst (blue) (101). (C) Immunohistochemical staining shows high
r (LV) section from a patient with end-stage heart failure caused by ischemic
nonfailing human heart. The MHC staining of a serial ICM section with an
urce of CCN1 (106). Other abbreviations as in Figure 3.g for
red w
to a h
nucle
riculaent results from attenuating apoptosis (111–113).
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rom induction of apoptosis; particularly, they cleave myo-
ardial contractile proteins and promote systolic dysfunction
113). Consistent with this property of caspases, treatment
ith caspase inhibitors after myocardial infarction has been
hown to preserve myocardial contractile proteins, reduce
ystolic dysfunction, and attenuate adverse ventricular re-
odeling (113). Thus, caspases are not only responsible for
ell loss by apoptosis but seem in addition to promote
ardiac dysfunction and adverse remodeling.
Beyond the stress-mediated apoptosis, stress-dependent
eregulation of survival pathways may affect the balance of
ormal myocyte apoptosis and self-renewal, leading to a
ontinuous cell loss in the adult heart. In light of the recent
dentification of resident cardiac stem cells, it is therefore
onceivable that a diminished self-renewal and “stemness”
f these cells with ageing or in response to stress factors may
ip the balance toward a greater loss of contractile cells,
esulting in cardiac dysfunction (5). Recent investigations
ave shown that cardiac hepatocyte growth factor/insulin-
ike growth factor-1 signaling plays a crucial role for
igration, proliferation, and differentiation of residual car-
iac stem cells, suggesting that these factors might be able
o tip the balance from cardiac cell loss toward cardiac
egeneration (114,115).
Taken together, there is increasing evidence showing that
ustained loss of cardiac cells by apoptosis, even when
ccurring in a low-grade manner, can cause cardiac dysfunc-
ion and ultimately lead to heart failure. In addition,
poptotic pathways seem to have direct effects on cardio-
yocyte contractility and remodeling. Although drug ther-
pies targeting potential upstream signaling mediators of
poptosis such as -adrenergic receptor blockers and inhib-
tors of the angiotensin II axis are standard in heart failure
herapy, novel approaches such caspase inhibitors and re-
enerative factors in addition to standard heart failure
herapy are likely to emerge as components of novel opti-
ized treatment of heart failure.
onclusions. The last decade has seen tremendous
rogress in the understanding of the molecular mechanisms
f heart failure. This article highlights some recent advances
n the analysis of molecular mechanisms related to cardiac
ypertrophy, oxidative stress, inflammation, angiogenesis,
nd apoptosis. Some of these findings may have important
mplications for the development of novel treatment strat-
gies in heart failure. In-depth understanding of molecular
echanisms of heart failure will finally provide valuable
nformation in the design of novel treatment strategies that
romote protective signaling pathways and prevent mal-
daptive responses, such as advanced hypertrophy, insuffi-
ient vascularization, and apoptosis.
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